- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We’re Reading: J&J Ends HIV Vaccine Trial; Deaths After Abortion Bans; Sanofi Looks to Hemophilia A Drug
Johnson & Johnson (J&J) ends late-stage HIV vaccine trial; mothers in states with abortion bans are almost 3 times more likely to die before, during, and after birth; Sanofi hopes to release a drug for hemophilia A in 2023.
J&J Will Stop HIV Vaccine Trial
Following evidence of ineffectiveness against infection prevention, Johnson & Johnson (J&J) will discontinue a late-stage worldwide trial of an HIV vaccine, Reuters reported. The news comes over a year after another unsuccessful vaccine study by J&J. A spokesperson who was a partner in the trial said that they will take the information from this trial put it to use in the future. The study started in 2019 at more than 50 locations, comprising about 3900 gay men and transgender people, who are deemed most susceptible to the infection.
States Banning Abortion More Likely to Have Maternal Deaths
Death in women during pregnancy, childbirth, or postpartum is almost 3 times more likely in states with abortion bans, Axios said, after reviewing a report from the Gender Equity Policy Institute. Almost 60% of US women live in states that ban or restrict abortion and other reproductive health care. In 2021, the maternal mortality rate in states with abortion bans was 2.4 times higher than that of states supporting abortion, according to the report, with women of color being the most affected.
Sanofi Strives to Introduce Hemophilia A Drug in 2023
French drug manufacturer Sanofi SA has high hopes for efanesoctocog alfa, its hemophilia A drug, in 2023, according to Reuters. The drug is being created in conjunction with Swedish drug producer Sobi; a decision by the FDA is expected by February 28. The marketing application was accepted by the FDA in 2022. An estimated 400 babies per year are born with the disorder, and possibly more.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
